Eli Lilly announced that its investigated GIP and GLP-1 inhibitor tirzepatide has demonstrated superiority over Novo Nordisk's Ozempic in a Phase III study.The SURPASS-2...
Editor's Note: Welcome to Inside Out, our weekly round up of stories about Staten Islanders making waves, being seen, supporting our community, and making...